Alexander EdwardDela CruzDrilonMD

PubMed

• Activating point mutations in the MET kinase domain represent a unique molecular subset of lung cancer and other malignancies targetable with MET inhibitors.
  Federica Pecci, Seshiru Nakazawa, Biagio Ricciuti, Guilherme Harada, Jessica K Lee, Joao V Alessi, Adriana Barrichello, Victor R Vaz, Giuseppe Lamberti, Alessandro Di ...> ;Cancer Discovery. 2024 Apr 3
• Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
  Mari Nakazawa, Guilherme Harada, Paola Ghanem, Adrian Bubie, Lesli A Kiedrowski, Joseph C Murray, Kristen A Marrone, Susan C Scott, Stefanie Houseknecht, Christina J F...> ;Cancer Research Communications. 2024 Mar 14
• 3 citations
  Precision Oncology: 2023 in Review.
  Suehnholz, S., Chakravarty, D., Murciano-Goroff, Y., Drilon, A.> ;Cancer Discovery. 2023 Dec 12
• Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
  Yun Fan, Alexander Drilon, Chao-Hua Chiu, Herbert H F Loong, Salvatore Siena, Maciej Krzakowski, Rafal Dziadziuszko, Harald Zeuner, Cloris Xue, Matthew G Krebs> ;Clinical Lung Cancer. 2024 Mar 1
• Spontaneous Bilateral Chylothorax Development During Alectinib Therapy for-Rearranged NSCLC-A Case Report.
  Bajaj, S., Chow, A., Drilon, A., Kalchiem-Dekel, O.> ;JTO Clinical and Research Reports. 2023 Dec 1
• 1 citations
  Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and...
  Soo-Ryum Yang, Erika Gedvilaite, Ryan Ptashkin, Jason Chang, John Ziegler, Douglas A Mata, Liliana B Villafania, Khedoudja Nafa, Jaclyn F Hechtman, Ryma Benayed, Ahmet...> ;Journal of Thoracic Oncology. 2024 Mar 1
• Decision-making as discovery: Vetting clinical research in a leading precision oncology service.
  Alberto Cambrosio, Jonah Campbell, Alexander E Drilon, Peter Keating, Jess B Polk> ;Sociology of Health & Illness. 2024 Mar 1
• 2 citations
  Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
  Shivaani Kummar, Lin Shen, David S Hong, Ray McDermott, Vicki L Keedy, Michela Casanova, George D Demetri, Afshin Dowlati, Soledad Gallego Melcón, Ulrik N Lassen, Serg...> ;Cancer. 2023 Dec 1
• Brief Report: Tyrosine Kinase Inhibitors for Lung Cancers That Inhibit MATE-1 Can Lead to "False" Decreases in Renal Function.
  Monica F Chen, Guilherme Harada, Dazhi Liu, Ray DeMatteo, Christina Falcon, Clare Wilhelm, Mark G Kris, Alexander Drilon, Victoria Gutgarts> ;Journal of Thoracic Oncology. 2024 Jan 1
• Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors.
  Marcia S Brose, David S Hong, Alexander Drilon> ;JCO Precision Oncology. 2023 Sep 1
• -Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.
  Antoine Desilets, Matteo Repetto, Soo-Ryum Yang, Eric J Sherman, Alexander Drilon> ;Cancers. 2023 Aug 17
• Mitogen-Activated Pathway Kinase Inhibitor-Associated Retinopathy: Do Features Differ with Upstream versus Downstream Inhibition?
  Canestraro, J., Diamond, E., Francis, J., Foulsham, W., Harding, J., Drilon, A., Abramson, D.> ;Ocular Oncology and Pathology. 2023 Aug 1
• A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data.
  Matteo Repetto, Edoardo Crimini, Carmen Belli, Luca Boscolo Bielo, Liliana Ascione, Funda Meric-Bernstam, Alexander Drilon, Giuseppe Curigliano> ;European Journal of Cancer. 2023 Sep 1
• 10 citations
  SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
  Alexander Drilon, Manish R Sharma, Melissa L Johnson, Timothy A Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B Reddy, Allison S Harney, Mohamed Elsayed, Adam ...> ;Cancer Discovery. 2023 Aug 4
• 3 citations
  Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.
  Arielle Elkrief, Igor Odintsov, Vladimir Markov, Rebecca Caeser, Pawel Sobczuk, Sam E Tischfield, Umesh Bhanot, Chad M Vanderbilt, Emily H Cheng, Alexander Drilon, Gre...> ;Journal of Thoracic Oncology. 2023 Sep 1
• Response to Repotrectinib After Development ofResistance Mutations on First- and Second-Generation TRK Inhibitors.
  Monica F Chen, Soo-Ryum Yang, Jinru Shia, Jeffrey Girshman, Sippy Punn, Clare Wilhelm, Mark G Kris, Emiliano Cocco, Alexander Drilon, Nitya Raj> ;JCO Precision Oncology. 2023 May 1
• In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC".
  Yonina R Murciano-Goroff, Sabrina T Lin, Clare Wilhelm, Alexia Iasonos, Alexander Drilon> ;Journal of Thoracic Oncology. 2023 May 1
• 3 citations
  Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
  Julia Rotow, Jyoti D Patel, Matthew P Hanley, Helena Yu, Mark Awad, Jonathan W Goldman, Hovav Nechushtan, Matthias Scheffler, Chih-Hsi S Kuo, Senthil Rajappa, Guilherm...> ;Clinical Cancer Research. 2023 Aug 15
• 1 citations
  Trends in location of death for individuals with metastatic lung cancer in the United States.
  Urvish Jain, Bhav Jain, Edward Christopher Dee, Simar Singh Bajaj, Joseph Alexander Paguio, Jasper Seth Yao, Daniel R Gomez, Leo Anthony Celi, Alexander Drilon> ;American Journal of Surgery. 2023 Jul 1
• 19 citations
  Rare molecular subtypes of lung cancer.
  Guilherme Harada, Soo-Ryum Yang, Emiliano Cocco, Alexander Drilon> ;Nature Reviews. Clinical Oncology. 2023 Apr 1
• 5 citations
  Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics.
  Jess B Polk, Jonah Campbell, Alexander E Drilon, Peter Keating, Alberto Cambrosio> ;Social Science & Medicine. 2023 May 1
• 1 citations
  Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib.
  Emily Miao, Jordan E Eichholz, Emily S Lebow, Jessica Flynn, Zhigang Zhang, Henry Walch, Harper Hubbeling, Kathryn Beal, Nelson S Moss, Kenny K Yu, Alicia Meng, Daniel...> ;Lung Cancer. 2023 Apr 1
• Response to Provenzano et al. and De Carlo et al.
  Or Kalchiem-Dekel, Christine M Bestvina, Justin F Gainor, Alexander Drilon, Jessica J Lin> ;Journal of Thoracic Oncology. 2023 Feb 1
• 6 citations
  Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib.
  Yonina R Murciano-Goroff, Christina J Falcon, Sabrina T Lin, Christina Chacko, Grace Grimaldi, Dazhi Liu, Clare Wilhelm, Alexia Iasonos, Alexander Drilon> ;Journal of Thoracic Oncology. 2023 May 1
• 1 citations
  Testing methods to diagnose TRK fusion cancer - a plain language summary and patient perspective.
  Erin R Rudzinski, Alexander Drilon, Amy Moore, Susan Spinosa, Michaela Willi, Theodore W Laetsch> ;Future Oncology. 2022 Dec 1
• Join now to see all